The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function (Q35652459)

9 August 2017

The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function (English)

1 reference

9 August 2017

1 reference

Annkristin Heine

1

1 reference

9 August 2017

Stefanie Andrea Erika Held

2

1 reference

9 August 2017

Solveig Nora Daecke

3

1 reference

9 August 2017

Kati Riethausen

4

1 reference

9 August 2017

Philipp Kotthoff

5

1 reference

9 August 2017

Chrystel Flores

6

1 reference

9 August 2017

Christian Kurts

7

1 reference

9 August 2017

Peter Brossart

8

1 reference

9 August 2017

language of work or name

English

0 references

publication date

4 June 2015

1 reference

9 August 2017

1 reference

9 August 2017

10

1 reference

9 August 2017

6

1 reference

9 August 2017

e0128897

1 reference

Creative Commons Attribution 4.0 International

9 August 2017

start time

4 June 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4456373

Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4456373

Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4456373

VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4456373

Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4456373

Cross-priming in health and disease.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4456373

Physiology and therapeutics of vascular endothelial growth factor in tumor immunosuppression

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4456373

Generation of antigen-specific CTL responses using RGS1 mRNA transfected dendritic cells

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4456373

c-Rel regulates interleukin 12 p70 expression in CD8(+) dendritic cells by specifically inducing p35 gene transcription.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4456373

VEGF as a mediator of tumor-associated immunodeficiency

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4456373

Immunobiology of dendritic cells

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4456373

Axitinib, a selective inhibitor of vascular endothelial growth factor receptor, exerts an anticancer effect in melanoma through promoting antitumor immunity.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4456373

The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4456373

Imatinib mesylate and nilotinib affect MHC-class I presentation by modulating the proteasomal processing of antigenic peptides

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4456373

Regulation of dectin-1-mediated dendritic cell activation by peroxisome proliferator-activated receptor-gamma ligand troglitazone

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4456373

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4456373

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

25 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0128897

Dendritic cell development and survival require distinct NF-kappaB subunits

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26042424

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Secondary lymphoid-tissue chemokine (SLC) is chemotactic for mature dendritic cells

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26042424

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Immunotherapy in renal cell carcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26042424

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1371/JOURNAL.PONE.0128897

1 reference

9 August 2017

0 references

1 reference

9 August 2017

1 reference